Optegra first to use cataract laser in UK

Article

Optegra is the first to offer the LensAR cataract laser in its London eye hospital.

Optegra is the first to offer the LensAR cataract laser in its London eye hospital.

The LensAR system, launched by Topcon, will be operated by a team of consultant ophthalmic surgeons led by Director of Laser Cataract Surgery for Optegra, Sundeep Kheterpal.

CE-marked and user-friendly, the system has a servo-controlled docking system that features a 'no corneal touch' liquid patient interface. This reportedly improves patient comfort and avoids compression and distortion to the cornea.

Mr Kheterpal commented, "Optegra has invested in this latest equipment to ensure we continue to offer the best possible service to our patients. Suitable for treatment of patients having both cataract surgery and Clarivu permanent lens replacement, the LensAR system has been designed to enhance the accuracy of surgery."

"The advantages of LensAR include full 3D custom imaging (CSI) of each individual eye, both posterior and anterior, to ensure precision and reproducibility. This enables the laser technology to perform laser incisions, which are more consistent and precise than ever before. The imaging is fully automated and there are multiple screens for ultimate accuracy and detail, leading to a most highly-informed diagnosis and accurate surgical procedure."

Optometrists and physicians wishing to offer their patients this cataract laser treatment are welcome to contact Hospital Manager Farzam Jafari, Optegra Eye Hospital, London, on +44 800 358 0825.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis, talks about how her research at the Glaucoma 360 symposium
I. Paul Singh, MD, an anterior segment and glaucoma specialist, discusses the Glaucoma 360 conference, where he participated in a panel discussion on the use of artificial intelligence (AI) in glaucoma care.
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.